List of Excipients in Branded Drug DOPRAM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	DOPRAM	doxapram hydrochloride	0641-6018	BENZYL ALCOHOL
Hikma Pharmaceuticals USA Inc	DOPRAM	doxapram hydrochloride	0641-6018	WATER

DOPRAM Excipient Strategy and Commercial Opportunities for Doxapram Injection

Last updated: September 4, 2026

DOPRAM is the U.S. brand associated with doxapram hydrochloride injection, a short-acting respiratory stimulant used in selected settings involving respiratory depression. Its commercial opportunity is limited by low clinical utilization, generic competition, and the absence of meaningful modern patent exclusivity. The strongest product-development opportunities are differentiated parenteral presentations, improved container systems, pharmacy workflow advantages, and supply reliability rather than new chemical-entity protection.

What is DOPRAM and how is doxapram supplied?

DOPRAM contains doxapram hydrochloride, a centrally acting respiratory stimulant administered by injection. The conventional product is an aqueous sterile solution intended for intravenous administration and, depending on the approved labeling and clinical setting, other parenteral routes.

Attribute	DOPRAM / doxapram injection
Active ingredient	Doxapram hydrochloride
Therapeutic category	Respiratory stimulant
Dosage form	Sterile injectable solution
Typical strength	20 mg/mL
Regulatory pathway	Legacy NDA and/or generic injectable pathways
Primary commercial constraint	Small and specialized hospital market
Main formulation concern	pH control, chemical stability, sterility, and container compatibility
Patent profile	Legacy compound with no expected meaningful composition-of-matter exclusivity

The product is materially different from a conventional oral generic. A parenteral formulation must satisfy sterility, particulate, extractables and leachables, container-closure integrity, endotoxin, stability, and administration requirements. Excipient selection therefore affects both product performance and regulatory burden.

FDA labeling identifies doxapram hydrochloride injection as a sterile aqueous formulation and describes the product's clinical use, dosage, warnings, and administration requirements. The inactive-ingredient profile is narrow, reflecting the limited need for functional excipients in a small-molecule injectable solution (U.S. Food and Drug Administration [FDA], n.d.-a).

What excipients are used in DOPRAM injection?

DOPRAM's formulation strategy is based on a minimal excipient system. Public product information identifies water for injection as the principal vehicle and indicates the use of acetate and acetic acid components for pH adjustment or buffering. Exact quantitative composition should be treated as product-specific because labels often disclose inactive ingredients qualitatively or within permitted concentration ranges.

Excipient or component	Likely function	Commercial relevance
Water for Injection	Vehicle	Required for parenteral quality and sterility control
Sodium acetate	Buffering and pH control	Can support pH stability but adds ionic strength
Acetic acid	pH adjustment	Controls final formulation pH
Doxapram hydrochloride	Active pharmaceutical ingredient	Determines solubility, pH profile, and compatibility

The principal formulation objective is to keep doxapram hydrochloride in solution across the labeled storage period while limiting degradation and interaction with the container system. A simple acetate-buffered formulation can reduce development complexity, but it leaves little room for excipient-based differentiation.

Why is a minimal excipient system commercially useful?

A low-excipient formulation has several advantages:

1. It reduces the number of inactive ingredients requiring qualification.
2. It limits the risk of hypersensitivity and incompatibility.
3. It simplifies sterile manufacturing and analytical testing.
4. It supports a clean label for hospital pharmacy use.
5. It may reduce the cost of goods.

The disadvantages are narrower formulation flexibility and greater dependence on the intrinsic stability of the active ingredient. A developer cannot assume that a formulation change is commercially neutral. New buffers, chelators, antioxidants, surfactants, or tonicity agents can alter pH, osmolality, degradation pathways, extractables, and administration compatibility.

What excipient strategies could improve DOPRAM?

The most credible strategy is a controlled reformulation that preserves the existing clinical and regulatory profile while improving manufacturability, stability, or use in hospital settings.

Buffer optimization

Acetate is a logical buffer system for an acidic injectable solution. A developer could assess whether a narrower buffer concentration or adjusted acetate-to-acetic-acid ratio improves:

• Long-term assay stability
• Resistance to pH drift
• Compatibility with glass or polymer containers
• Stability after withdrawal into a syringe
• Compatibility with infusion systems

The commercial benefit would be strongest if the reformulation enables a longer shelf life, a broader storage range, or fewer shipping restrictions. Buffer optimization alone is unlikely to create durable market exclusivity unless it produces a clinically meaningful or technically difficult product.

Antioxidant or chelator evaluation

An antioxidant or chelating agent could be considered if oxidative degradation or trace-metal catalysis limits stability. Such additions require a clear quality rationale. They can create new risks, including injection-site tolerability, compatibility problems, regulatory scrutiny, and additional analytical requirements.

A chelator such as edetate may be technically useful in some injectable products, but its use in doxapram would require evidence that it improves stability without changing safety or administration characteristics. An antioxidant could also complicate impurity control if it degrades or interacts with the active ingredient.

Tonicity adjustment

Doxapram injection may not require a dedicated tonicity agent if the formulation's ionic composition and concentration produce acceptable osmolality for the intended route. Sodium chloride or another tonicity modifier could improve tolerability, but it would also change the formulation's ionic strength and potentially affect stability.

Tonicity adjustment is most commercially relevant for a ready-to-administer product intended for direct intravenous use. The value is lower if the product is routinely diluted before administration.

Surfactant avoidance

Surfactants are generally unnecessary for a clear, soluble small-molecule injection. Their inclusion could increase the risk of foaming, adsorption, particulate formation, and compatibility problems. A surfactant-free formulation would be preferable unless the active ingredient shows adsorption or precipitation in the target container.

Preservative-free positioning

A preservative-free, single-dose presentation is commercially attractive for hospital products. It reduces concerns about preservative exposure and can support use in critical-care or perioperative settings. The tradeoff is higher packaging cost and more demanding aseptic manufacturing economics.

A multidose preserved product may reduce packaging cost per dose but is less attractive for a low-volume injectable used in institutional settings. Preservatives also create route-specific safety and compatibility considerations.

What formulations are protected by DOPRAM patents?

DOPRAM is unlikely to benefit from active composition-of-matter protection. Doxapram was developed decades ago, and any original compound patent would have expired long before the current generic market.

Patent category	Expected status	Commercial implication
Doxapram composition of matter	Expired	No meaningful molecule-level exclusivity
Original therapeutic-use patents	Expired or commercially immaterial	Limited blocking power
Legacy injectable formulation patents	Expected to be expired	Does not prevent standard generic injection
Modern formulation patents	Possible only for a new, non-obvious formulation	Could support limited differentiation
Container or device patents	Potentially available	May protect presentation rather than the drug itself
Manufacturing-process patents	Potentially available	Could protect yield, impurity control, or sterile processing

The strongest patent opportunity would involve a formulation that solves a documented technical problem, such as improved stability in a polymeric container, extended in-use stability after dilution, or a novel ready-to-administer presentation. A patent covering only routine pH adjustment or substitution of one pharmaceutically acceptable buffer for another would face substantial obviousness risk.

What is the Orange Book status of DOPRAM?

The Orange Book does not create exclusivity for a product merely because the product is listed. It records approved drug products, therapeutic equivalence information, patents submitted by NDA holders, and certain exclusivity periods. A legacy doxapram product should be evaluated for current NDA status, listed patents, reference listed drug designation, and available therapeutically equivalent products in the latest FDA Orange Book (FDA, n.d.-b).

For commercial planning, the key conclusions are:

• No new chemical entity exclusivity should remain.
• Pediatric exclusivity is not expected to be relevant.
• Orphan-drug exclusivity is not a known commercial barrier for standard doxapram injection.
• Any remaining listing would be product-specific and should not be confused with active patent protection.
• A new formulation would need its own approval strategy and could potentially qualify for three-year exclusivity if it contains an approved active ingredient and is supported by new clinical investigations essential to approval, subject to FDA requirements.

When does DOPRAM lose exclusivity?

DOPRAM's meaningful exclusivity was lost long ago through expiration of the original compound and product protections. The current market is therefore governed by generic approval, manufacturing capability, supply reliability, and hospital purchasing rather than by an approaching patent cliff.

A new sponsor could create limited regulatory exclusivity around a reformulated product, but the duration and scope would depend on the approval pathway and the type of supporting data. A formulation-only ANDA generally would not create the same exclusivity as a new NDA supported by clinical investigations.

Are there Paragraph IV challenges involving doxapram?

Paragraph IV litigation is not expected to be a major current issue for doxapram injection. Paragraph IV certifications are relevant when an ANDA applicant challenges an Orange Book-listed patent as invalid, unenforceable, or not infringed. For an old injectable product with no commercially important unexpired patents, the more likely pathway is approval based on the reference product and any applicable FDA requirements rather than a high-value patent challenge.

The absence of major Paragraph IV activity does not eliminate regulatory risk. Injectable generics can face:

• Product-specific bioequivalence requirements
• Sterility and aseptic-processing deficiencies
• Manufacturing-site observations
• Drug-shortage-related supply obligations
• Container-closure and particulate failures
• Labeling and concentration differences

These risks are operational rather than patent-centered.

How strong is the DOPRAM patent estate?

The patent estate is weak for the legacy product and potentially moderate for a genuinely differentiated reformulation.

Asset type	Patent strength	Reason
Original doxapram molecule	Very low	Historical protection expired
Conventional aqueous injection	Low	Routine formulation architecture
Acetate-buffered formulation	Low to moderate	Vulnerable if claimed broadly
Polymer-compatible presentation	Moderate	Stronger if supported by specific stability data
Ready-to-use syringe	Moderate	Protectable through device and formulation combinations
Novel dilution-stable formulation	Moderate to strong	Requires reproducible technical advantage
Manufacturing impurity-control process	Moderate	Depends on unexpected result and claim scope

A defensible patent program would use layered claims: composition, concentration range, pH range, impurity profile, container system, storage condition, in-use stability, and manufacturing process. Broad claims should be supported by comparative data across multiple buffer systems and container materials.

What commercial opportunities exist for DOPRAM excipient innovation?

The market is small, but several opportunities can improve product value.

Ready-to-use prefilled syringes

A prefilled syringe could reduce dose preparation, support emergency use, and decrease medication-error risk. The principal development issues are syringe-material compatibility, adsorption, extractables and leachables, plunger performance, sterilization, and stability over the proposed shelf life.

The presentation may command a premium even if the active ingredient is generic because hospitals often value reduced preparation time and standardized dosing.

Unit-dose ampoules or vials

A reliable unit-dose product can compete on availability and pharmacy efficiency. Clear labeling, terminally sterilizable packaging where feasible, tamper evidence, and low-volume presentations can support institutional purchasing.

The commercial case is strongest when the product addresses recurring shortages or replaces a labor-intensive pharmacy-compounded presentation.

Extended shelf life

Shelf-life extension can reduce inventory write-offs and improve wholesaler acceptance. It can also support broader distribution outside large hospitals. The formulation strategy should focus on pH control, oxygen exposure, light protection, container selection, and impurity formation.

Low-sorption container systems

A polymer container or syringe may improve handling and reduce breakage compared with glass. The formulation must be tested for adsorption, permeation, closure interaction, and extractables. A polymer presentation could support a formulation patent if the interaction between the excipient system and container produces an unexpected stability advantage.

Hospital shortage and supply-reliability positioning

Because doxapram is a specialized hospital product, procurement decisions may depend more on continuity of supply than on broad physician demand. A sponsor with dependable sterile manufacturing, dual sourcing, and adequate inventory could capture share without owning strong patents.

How does DOPRAM compare with competing respiratory-support products?

Doxapram competes indirectly with respiratory-support interventions rather than with a single equivalent drug. Clinical alternatives may include ventilatory support, airway management, reversal agents where appropriate, caffeine or other respiratory stimulants in specific populations, and treatment of the underlying cause of respiratory depression.

Factor	Doxapram injection	Non-drug respiratory support
Administration	Parenteral drug	Device or procedural intervention
Main value	Pharmacologic stimulation	Direct ventilation or oxygenation
Formulation opportunity	High for presentation and stability	Not applicable
Patent barrier	Low for active ingredient	Device-specific
Hospital purchasing driver	Availability and ease of use	Clinical protocol and equipment
Commercial risk	Low volume, narrow indication	Substitution by standard supportive care

Doxapram's commercial positioning should focus on defined rescue or perioperative use, not broad respiratory-care replacement.

What regulatory pathway applies to a new DOPRAM formulation?

A sponsor changing the formulation must select a pathway based on the desired label, reference product, clinical data, and extent of formulation change.

ANDA strategy

An ANDA may be appropriate when the proposed product is pharmaceutically equivalent and bioequivalent to a reference listed drug. Injectable products often have simpler in vivo bioequivalence requirements than oral dosage forms, but the sponsor must still demonstrate sameness or acceptable differences in inactive ingredients and meet product-quality requirements.

A new excipient, unusual concentration, or different route can complicate the ANDA strategy.

505(b)(2) strategy

A 505(b)(2) application may be suitable for a differentiated formulation, delivery system, strength, or administration method that relies partly on FDA findings for an existing product. This route can support a commercial product with improved presentation or handling characteristics while avoiding a full new-drug development program.

The sponsor must evaluate patent certification, exclusivity, bridging data, human factors, and any clinical evidence needed to support the reformulated product.

Manufacturing and quality requirements

Critical development work includes:

• Assay and related-substance methods
• pH and osmolality
• Visible and subvisible particulate testing
• Sterility and bacterial endotoxin testing
• Container-closure integrity
• Extractables and leachables
• In-use and dilution stability
• Photostability
• Shipping qualification
• Compatibility with common infusion materials

FDA's injection guidance and current product-specific requirements should govern the development program (FDA, 2015).

What licensing and partnership opportunities exist?

Doxapram offers limited conventional licensing value because the active ingredient is old and generic. Partnership opportunities are more credible in three areas:

1. Licensing a ready-to-use injectable platform.
2. Acquiring a sterile manufacturing or fill-finish capability.
3. Partnering with a hospital-focused distributor with established purchasing contracts.

A formulation patent could increase licensing value if it covers a measurable advantage, such as a prefilled syringe with long-term stability, a low-particulate container system, or a formulation that remains stable after dilution under routine hospital conditions.

What generic launch scenarios exist for DOPRAM?

Low-cost conventional generic

This product competes on price and supply. It has the lowest development cost but the weakest differentiation.

Premium ready-to-administer product

A prefilled syringe or standardized unit dose can command a higher price through workflow benefits. Device and container costs will be higher.

Shortage-driven launch

A sponsor can target a supply gap with a conventional formulation and hospital contracting. The principal assets are manufacturing readiness and regulatory execution.

Reformulated 505(b)(2) product

A new formulation or presentation could support a differentiated label and limited regulatory exclusivity. Development cost and regulatory complexity would also increase.

What geographic markets offer the best opportunity?

The United States offers the clearest regulatory framework but has a small, price-sensitive institutional market. Europe and other regulated markets may offer opportunities through national hospital tenders, although reimbursement and registration requirements vary by country.

Emerging markets may have less competition in sterile injectables but present greater risks involving local registration, pharmacopoeial requirements, cold-chain or distribution controls, and procurement pricing. A regional strategy should prioritize countries with established hospital demand and reliable sterile-product distribution.

Key Takeaways

• DOPRAM is a legacy doxapram hydrochloride injectable product with limited or no meaningful active-molecule exclusivity.
• The formulation is based on a simple sterile aqueous system with acetate and acetic-acid pH control.
• Broad excipient substitution is unlikely to create strong patent protection.
• The best commercial opportunities are ready-to-use syringes, unit-dose packaging, longer shelf life, container compatibility, and reliable supply.
• A conventional generic would face price pressure and low market volume.
• A differentiated product may be better suited to a 505(b)(2) strategy than to a standard ANDA.
• The strongest potential patents would cover a specific formulation-container combination, in-use stability advantage, or manufacturing process.
• Commercial success will depend more on sterile manufacturing, hospital contracting, and supply continuity than on legacy DOPRAM patents.

FAQs

Is doxapram injection still commercially viable?

Yes, but as a focused hospital product rather than a broad primary-care medicine. Viability depends on reliable sterile manufacturing, adequate distribution, and a presentation that reduces pharmacy workload.

Can a new excipient create exclusivity for DOPRAM?

A new excipient alone is unlikely to create meaningful exclusivity. A patent position is stronger when the excipient produces an unexpected and documented improvement in stability, compatibility, safety, or administration.

Is a preservative-free DOPRAM product commercially attractive?

Yes. A preservative-free single-dose presentation aligns with hospital and critical-care preferences, although it increases packaging and aseptic manufacturing costs.

Would a prefilled doxapram syringe qualify for a new patent?

Potentially. Patentability would depend on the specific formulation, syringe materials, stability results, dose configuration, and non-obvious technical advantage.

Is biosimilar competition relevant to DOPRAM?

No. Doxapram is a synthetic small molecule, not a biologic. Competition would arise through generic or reformulated drug products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2015). ANDAs for certain highly purified synthetic peptides: Guidance for industry. https://www.fda.gov
2. U.S. Food and Drug Administration. (n.d.-a). Doxapram hydrochloride injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
4. United States Pharmacopeia. (2024). General chapter <1>: Injections and implanted drug products. United States Pharmacopeial Convention.
5. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. https://www.ich.org